Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M

Paul Schloesser

Associate Editor

Agios and Alnylam have agreed on an exclusive global licensing deal worth $147.5 million for Agios to take over the development and commercialization of a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?

Agios to take over Al­ny­lam’s pre­clin­i­cal siR­NA blood dis­or­der as­set in a deal worth $147.5M

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Agios to take over Alnylam’s preclinical siRNA blood disorder asset in a deal worth $147.5M

Jazz wins approval for bispecific in biliary tract cancer

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B

FDA adcomm raises risk questions on AstraZeneca’s Andexxa

At Jefferies, all that manufacturers want to talk about is GLP-1s

Are programs with compounded GLP-1s safe for your population?